These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37881343)

  • 1. Access and use of WHO essential medicines in Italy.
    Petrella A; Fortinguerra F; Cangini A; Pierantozzi A; Trotta F
    Front Public Health; 2023; 11():1211208. PubMed ID: 37881343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using the WHO essential medicines list to assess the appropriateness of insurance coverage decisions: a case study of the Croatian national medicine reimbursement list.
    Jeličić Kadić A; Žanić M; Škaričić N; Marušić A
    PLoS One; 2014; 9(10):e111474. PubMed ID: 25337860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A quantitative comparison between the essential medicines for rheumatic diseases in children and young people in Africa and the WHO model list.
    Slamang W; Scott C; Foster HE
    Pediatr Rheumatol Online J; 2024 Jul; 22(1):63. PubMed ID: 38965620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Essential cancer medicines in the national lists of countries of the WHO South-East Asia Region: a descriptive assessment.
    Chivukula MV; Tisocki K
    WHO South East Asia J Public Health; 2018 Sep; 7(2):90-98. PubMed ID: 30136667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey.
    Fundytus A; Sengar M; Lombe D; Hopman W; Jalink M; Gyawali B; Trapani D; Roitberg F; De Vries EGE; Moja L; Ilbawi A; Sullivan R; Booth CM
    Lancet Oncol; 2021 Oct; 22(10):1367-1377. PubMed ID: 34560006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multidisciplinary review of the policy, intellectual property rights, and international trade environment for access and affordability to essential cancer medications.
    Baxi SM; Beall R; Yang J; Mackey TK
    Global Health; 2019 Sep; 15(1):57. PubMed ID: 31533850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of evidence supporting the Federation of Bosnia and Herzegovina reimbursement medicines lists: role of the WHO Essential Medicines List, Cochrane systematic reviews and technology assessment reports.
    Mahmić-Kaknjo M; Marušić A
    Eur J Clin Pharmacol; 2015 Jul; 71(7):825-33. PubMed ID: 25956715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A quantitative comparison of essential cardiovascular medicines from countries in the Southern African Development Community to the WHO model essential medicines list.
    Naicker I; Suleman F; Perumal-Pillay VA
    J Pharm Policy Pract; 2022 Dec; 15(1):97. PubMed ID: 36482421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe.
    Cherny NI; Sullivan R; Torode J; Saar M; Eniu A
    Ann Oncol; 2017 Nov; 28(11):2633-2647. PubMed ID: 28950323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Essential Medicines in a High Income Country: Essential to Whom?
    Duong M; Moles RJ; Chaar B; Chen TF;
    PLoS One; 2015; 10(12):e0143654. PubMed ID: 26650544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanding medicines for neurologic disorders on the WHO Model List.
    Rimmer K; Shah H; Thakur K
    Neurology; 2017 Mar; 88(10):e87-e91. PubMed ID: 28265046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Essential Medicines List Implementation Dynamics: A Case Study Using Brazilian Federal Medicines Expenditures.
    Magarinos-Torres R; Lynd LD; Luz TCB; Marques PEPC; Osorio-de-Castro CGS
    Basic Clin Pharmacol Toxicol; 2017 Sep; 121(3):181-188. PubMed ID: 28371342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Essential medicines availability is still suboptimal in many countries: a scoping review.
    Mahmić-Kaknjo M; Jeličić-Kadić A; Utrobičić A; Chan K; Bero L; Marušić A
    J Clin Epidemiol; 2018 Jun; 98():41-52. PubMed ID: 29452222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Essential cancer medicines: adding feasibility to the magnitude of clinical benefit value chain.
    Roitberg F; Amaral T; Cherny NI; Giuliani R; Latino NJ; Galotti M; Bricalli G; Curigliano G; Pentheroudakis G; Trapani D
    ESMO Open; 2023 Oct; 8(5):101617. PubMed ID: 37672862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Updating the WHO Model Lists of Essential Medicines to promote global access to the most cost-effective and safe medicines for mental disorders.
    Papola D; Ostuzzi G; Todesco B; Gastaldon C; Hanna F; Chatterjee S; van Ommeren M; Barbui C
    Lancet Psychiatry; 2023 Oct; 10(10):809-816. PubMed ID: 37475123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Global status of essential medicine selection: a systematic comparison of national essential medicine lists with recommendations by WHO.
    Piggott T; Nowak A; Brignardello-Petersen R; Cooke GS; Huttner B; Schünemann HJ; Persaud N; Magrini N; Moja L
    BMJ Open; 2022 Feb; 12(2):e053349. PubMed ID: 35144950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modernizing the World Health Organization List of Essential Medicines for Preventing and Controlling Cardiovascular Diseases.
    Kishore SP; Blank E; Heller DJ; Patel A; Peters A; Price M; Vidula M; Fuster V; Onuma O; Huffman MD; Vedanthan R
    J Am Coll Cardiol; 2018 Feb; 71(5):564-574. PubMed ID: 29406862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticancer medicines in Pakistan: An analysis of essential medicines lists.
    Shukar S; Anjum R; Zhang J; Babar ZU; Mobeen I; Yang C
    J Oncol Pharm Pract; 2024 Jan; 30(1):46-54. PubMed ID: 37006130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GRADE Concept 7: Issues and Insights Linking Guideline Recommendations to Trustworthy Essential Medicine Lists.
    Piggott T; Moja L; Jenei K; Kredo T; Skoetz N; Banzi R; Trapani D; Leong T; McCaul M; Lavis JN; Akl EA; Nonino F; Iorio A; Laurson-Doube J; Huttner BD; Schünemann HJ
    J Clin Epidemiol; 2024 Feb; 166():111241. PubMed ID: 38123105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Essential Medicines at the National Level: The Global Asthma Network's Essential Asthma Medicines Survey 2014.
    Bissell K; Ellwood P; Ellwood E; Chiang CY; Marks GB; El Sony A; Asher I; Billo N; Perrin C;
    Int J Environ Res Public Health; 2019 Feb; 16(4):. PubMed ID: 30791442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.